Endocannabinoid system and CNR1 gene polymorphisms in schizophrenia and addictive disorders

Authors

  • I. Martínez-Gras Servicio de Salud Mental de Retiro Madrid (Spain)
  • J. Hoecnika Servicio de Psiquiatría Hospital Universitario Doce de Octubre Madrid (Spain)
  • E. Pérez-Hernández Departamento de Psicología Básica Universidad Complutense Madrid (Spain)
  • R. Rodríguez-Jiménez Servicio de Psiquiatría Hospital Universitario Doce de Octubre Madrid (Spain)
  • G. Ponce Servicio de Psiquiatría Hospital Universitario Doce de Octubre Madrid (Spain)
  • M. A. Jiménez-Arriero Servicio de Psiquiatría Hospital Universitario Doce de Octubre Madrid (Spain)
  • J. Ramos-Atance Departamento de Bioquímica Universidad Complutense Madrid (Spain)
  • T. Palomo Servicio de Psiquiatría Hospital Universitario Doce de Octubre Madrid (Spain)
  • G. Rubio Servicio de Salud Mental de Retiro Madrid (Spain)

Keywords:

cannabis, CNR1, schizophrenia, addictions

Abstract

Substance abuse is the most prevalent comorbid psychiatric condition associated with schizophrenia. Cannabis is a drug frequently used for schizoprenic patients. In the last decades the endocannabinoid system and their endogenous ligands have been discovered. Endogenous cannabinoids act in the brain on cannabinoid CB1 receptor. On the other hand this system may be involved in several brain functions through neuromodulation dopaminergic and other neurotransmitter system involved in schizophrenic and substance abuse disorders. Advances of genetic research have addressed the focus on the search of candidate genes for both disorders. In this review we have summarized the studies published about the CNR1 gene on szhizophrenia and substance abuse disorders

Published

2007-03-01

How to Cite

Martínez-Gras, I., et al. “Endocannabinoid System and CNR1 Gene Polymorphisms in Schizophrenia and Addictive Disorders”. Actas Españolas De Psiquiatría, vol. 35, no. 2, Mar. 2007, pp. 122-9, https://actaspsiquiatria.es/index.php/actas/article/view/583.

Issue

Section

Review